| Name | Title | Contact Details |
|---|
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
Global Dosimetry Solutions, Inc. (GDS) is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Devon Medical is a King Of Prussia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Schnepp Health Care Center is deeply committed to providing the highest quality rehabilitation services. Our facility offers a full-time physical therapist with full-time assistants and specially trained restorative nursing staff that continues to work